Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 112OTHER 19NIH 6OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 18Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Prostatic Neoplasms 83Urinary Bladder Neoplasms 31Carcinoma, Renal Cell 9Carcinoma, Transitional Cell 8Kidney Neoplasms 7Recurrence 5Prostatic Hyperplasia 5Neoplasms 5Disease 5Testicular Neoplasms 3Pain, Postoperative 3Pain 3Non-Muscle Invasive Bladder Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Anxiety Disorders 3Sleep Initiation and Maintenance Disorders 2Penile Neoplasms 2Pancreatic Neoplasms 2Motor Activity 2Melanoma 2Lymphoma 2Carcinoma, Hepatocellular 2Carcinoma 2Breast Neoplasms 2Adenocarcinoma 2Acute Kidney Injury 2Wilms Tumor 1Vulvar Neoplasms 1Vomiting 1Uterine Cervical Neoplasms 1

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Triple Negative Breast Neoplasms × Genitourinary × Clear all
NCT04142931 2021-03-24

Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors

Sheba Medical Center

Phase 1 Unknown
30 enrolled
BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡